Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10982903 | 1.00 | ENPEP (0.40) | ENPEPALDH1A1CA2CA1AKR1B1 | |
| SCHEMBL14940740 | 1.00 | ENPEP (0.40) | ENPEPALDH1A1CA2CA1AKR1B1 | |
| SCHEMBL31643061 | 0.96 | CTSD (0.42) | ENPEPALDH1A1CA2CA1AKR1B1 | |
| SCHEMBL30799828 | 0.91 | ENPEP (0.40) | ENPEPAKR1B1CTSDL3MBTL1 | |
| SCHEMBL8437180 | 0.89 | MME (0.37) | ALDH1A1CA2CA1AKR1B1MME | |
| SCHEMBL8437182 | 0.89 | MME (0.37) | ALDH1A1CA2CA1AKR1B1MME | |
| SCHEMBL8527615 | 0.88 | MME (0.43) | CA2CA1MMEECE1 | |
| SCHEMBL29961849 | 0.88 | MME (0.43) | CA2CA1MMEECE1 | |
| SCHEMBL8527609 | 0.88 | MME (0.43) | CA2CA1MMEECE1 | |
| Water SCHEMBL29655489 | 0.88 | MME (0.36) | ALDH1A1AKR1B1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| CN-119033924-B | Development and application of porcine infectious pleuropneumonia subunit vaccine | 吉林大学 | 2025-04-11 | — | — | CN | disclosed |
| US-12163188-B2 | Polymerase compositions and methods | Life Technologies Corporation (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230055565-A1 | POLYMERASE COMPOSITIONS & METHODS | Life Technologies Corporation (US) | 2023-02-23 | — | — | US | disclosed |
| US-11453909-B2 | Polymerase compositions and methods | Life Technologies Corporation (US) | 2022-09-27 | — | — | US | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453909-B2 | Polymerase compositions and methods | POLN, POLI, POLRMT | ENPEP 180/4885ALDH1A1 1832/4885CA2 4109/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | ENPEP 148/4885ALDH1A1 3706/4885CA2 3216/4885 |
| US-12163188-B2 | Polymerase compositions and methods | POLN, POLI, POLRMT | ENPEP 180/4885ALDH1A1 1832/4885CA2 4109/4885 |
| US-20230055565-A1 | POLYMERASE COMPOSITIONS & METHODS | POLN, POLI, POLRMT | ENPEP 194/4885ALDH1A1 1785/4885CA2 4089/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | ENPEP 681/4885ALDH1A1 2847/4885CA2 82/4885 |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ATP5ME, ATP5MF, ATP5MK | ENPEP 113/4885ALDH1A1 1687/4885CA2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.